Tagraxofusp-erzs

BIOLOGICAL7 trials

Sponsors

Stemline Therapeutics, Inc., M.D. Anderson Cancer Center, Jonsson Comprehensive Cancer Center, City of Hope Medical Center

Conditions

Acute Myeloid LeukemiaBlastic Plasmacytoid Dendritic Cell NeoplasmChronic Myelomonocytic LeukemiaChronic Myelomonocytic Leukemia-1Chronic Myelomonocytic Leukemia-2Myelodysplastic SyndromeMyelodysplastic/Myeloproliferative NeoplasmRecurrent Adult Lymphoblastic Lymphoma

Phase 1

SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission

TerminatedNCT02270463

Stemline Therapeutics, Inc.Acute Myeloid Leukemia

Start: 2015-02-28End: 2019-12-31Updated: 2024-10-17

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

TerminatedNCT05032183

M.D. Anderson Cancer CenterRecurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia +3

Start: 2022-02-17End: 2024-07-31Updated: 2025-08-11

Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes

Active, not recruitingNCT05038592

M.D. Anderson Cancer CenterChronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2 +1

Start: 2022-03-04End: 2027-01-29Target: 64Updated: 2026-01-21

Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia

WithdrawnNCT05720988

Jonsson Comprehensive Cancer CenterAcute Myeloid Leukemia

Start: 2024-08-03End: 2026-08-03Updated: 2024-03-08

Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant

RecruitingNCT06498973

City of Hope Medical CenterAcute Myeloid Leukemia, Myelodysplastic Syndrome

Start: 2025-01-28End: 2027-04-25Target: 43Updated: 2026-03-05

Phase 2

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

RecruitingNCT04216524

M.D. Anderson Cancer CenterBlastic Plasmacytoid Dendritic Cell Neoplasm

Start: 2020-05-29End: 2026-12-31Target: 40Updated: 2026-03-04

Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant

TerminatedNCT04317781

M.D. Anderson Cancer CenterBlastic Plasmacytoid Dendritic Cell Neoplasm

Start: 2020-03-27End: 2023-07-11Updated: 2024-07-31

Related Papers

Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study.

2025-05-111 citations

Tagraxofusp Maintenance Post-Hematopoietic Stem Cell Transplantation Provides Long-Term Survival and Manageable Safety for a Patient with Blastic Plasmacytoid Dendritic Cell Neoplasm

Blood2023-11-021 citations

Outcomes for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated with Frontline HCVAD-Based Chemotherapy

Blood2021-11-052 citations

Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients with Hematologic Malignancies

Blood2021-11-05

Phase 2 Study of Tagraxofusp Therapy for BPDCN Patients Post-Autologous or Post-Allogeneic Hematopoietic Cell Transplantation

Blood2020-11-044 citations

Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD)

Blood2016-12-0226 citations

SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS with Excess Blasts and Demonstrates Therapeutic Benefit in PDX Model

Blood2016-12-021 citations